Calcium channel blockers

A class of medicines that work by blocking calcium from moving into cells. The US label read for one calcium channel blocker says it may be used alone or with other blood pressure and angina medicines. It lists high blood pressure, and coronary artery disease in the forms chronic stable angina, vasospastic angina and angiographically documented disease in people without heart failure or an ejection fraction under 40%.

Also called Calcium channel blocker · Calcium antagonists

  • Drug
  • In this atlas

Overview

Technical summary

Class page. MeSH descriptor D002121 (Calcium Channel Blockers, last updated 2020-05-27) is an exact match, and its scope note gives the class description. The label read is the US prescribing label of one brand-name amlodipine besylate tablet (application NDA019787, effective 2023-02-15 in openFDA). The label describes amlodipine as a dihydropyridine calcium antagonist, so it does not stand for every member of the class. The label text read states no age range for its uses. This page gives no dose, no trial result and no guideline statement, and none of the label's warnings or interactions was recorded. Medicines of the class that have their own pages are filed under it.

Trials at a glance

The figures count the 11 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.

Trials
11
Phase 3 or 4
10
Recruiting
1
Regulatory decisions
0
Trials by phase (rows) and registry status (columns)
PhaseRecruitingNot yet recruitingCompletedSuspendedUnknown statusAll statuses
Phase 2001001
Phase 3012003
Phase 4104117
All phases1171111

Conditions these trials study

Sponsors with the most trials

The lead sponsor of each trial, as the registry names it.

And 4 more.

Drugs in this class

4 drugs in this atlas are filed under Calcium channel blockers, with the registry trials and FDA regulatory decisions this atlas holds for each. With Calcium channel blockers itself, the class has 60 distinct trials and 64 distinct FDA decisions; a trial or decision that two of them share counts once there.

About this drug

Level
Class
Mechanism
MeSH says these drugs act by selective inhibition of calcium influx through cellular membranes. A US label says the one it describes inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle.

Claims and evidence

Context People with hypertension or coronary artery disease, as described in the US label of a calcium channel blocker

Recipient
Recipient not specified
Population
Patients described in the indications section of the label: patients with hypertension, and patients with chronic stable angina, vasospastic angina, or angiographically documented coronary artery disease without heart failure or an ejection fraction under 40%.
Care setting
Prescription medicine, as described in the US label
Geography
United States (US drug label)
Life stage
Not stated in the passages read
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (label statement)
Eligibility: 4 inclusion criteria; exclusion criteria not stated
Included
  • Hypertension
  • Chronic stable angina
  • Vasospastic angina
  • Angiographically documented coronary artery disease in patients without heart failure or an ejection fraction under 40%
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    The US label of NORVASC (amlodipine besylate tablets, Viatris Specialty LLC, application NDA019787; the version dated 2023-02-15 in openFDA) calls the medicine a calcium channel blocker that may be used on its own or in combination with other antihypertensive and antianginal agents. It lists the treatment of hypertension, and coronary artery disease in three forms: chronic stable angina, vasospastic angina, and angiographically documented coronary artery disease in patients without heart failure or an ejection fraction under 40%. MeSH describes the class as drugs that act by selective inhibition of calcium influx through cellular membranes.

    Applies to Recipient not specified People with hypertension or coronary artery disease, as described in the US label of a calcium channel blocker

    Certainty method
    Not assessed
    Limitations
    This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The medicine is a dihydropyridine, so the label does not stand for every calcium channel blocker. The label text read states no age range. Contraindications, warnings, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-09
    Next evidence check due
    Not scheduled
    Sources and citations (3)
    1. Supports openFDA drug label record for NORVASC (amlodipine besylate tablets), Viatris Specialty LLC label: indications and class description

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 7367289c-b0b0-466a-83e2-558e2985c29f (manufacturer Viatris Specialty LLC, application NDA019787), returned on 2026-11-09. The label text is dated 2023-02-15 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
      How it applies
      The label sentences that call the medicine a calcium channel blocker and list hypertension and coronary artery disease.
      Retrieved
      Source effective date
      2023-02-15
      Source state
      Current
      Version fingerprint
      bf6df4ca425b576e31632a7221984d7eb04668134e654d030073338ba914819d
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Background openFDA drug label record for NORVASC (amlodipine besylate tablets), Viatris Specialty LLC label: indications and class description

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 7367289c-b0b0-466a-83e2-558e2985c29f (manufacturer Viatris Specialty LLC, application NDA019787), returned on 2026-11-09. The label text is dated 2023-02-15 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20230215.
      Retrieved
      Source effective date
      2023-02-15
      Source state
      Current
      Version fingerprint
      bf6df4ca425b576e31632a7221984d7eb04668134e654d030073338ba914819d
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    3. Supports MeSH scope note for descriptor D002121 (Calcium Channel Blockers)

      Dataset · U.S. National Library of Medicine · Edition MeSH linked-data record of the preferred concept M0003165 of descriptor D002121, fetched 2026-10-30. The scope note is on this concept record, not on the descriptor record. · MeSH: M0003165

      Locator
      scopeNote.@value
      How it applies
      MeSH scope note: what the class does.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      afa580433e9343662dc0028eebedb5b1943e77b266b29033c5597b5175cd8379
      Reuse basis
      The NLM web policies page (sha256 c8b7026b5c3fcfd1b0cb88755077f6a99a5f2159eecd42b0e7d1a5ad9b30ec55, hash only) says works produced by the U.S. government are not subject to copyright protection in the United States and asks users to acknowledge NLM as the source. Source: National Library of Medicine. This copy was fetched on 2026-10-30 and may not reflect the most current data. The raw bytes are committed in the atlas repository.

Clinical links

Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.

Registry records

Assembled by a program from ClinicalTrials.gov. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.

Registry trials 11

Record details

Record id
cardio:calcium-channel-blockers
Content hash
38fb7af65e3e3a53a1e86e71ecc6efa6ab3eed1f5c4b7cf4d61b0000cabf9f16